ResMed targets 12% to 14% EPS growth amid rising sleep therapy demand

ResMed is targeting core earnings per share (EPS) growth of 12% to 14% for the year, according to executives during a recent discussion. Chief Financial Officer Aaron Bloomer noted the company is aiming for this adjusted range despite an estimated $75 million impact from an Astral field safety notice.

The company expects core constant-currency revenue growth of 5% to 7%. CEO Mick Farrell highlighted a massive addressable market of 2.7 billion people with sleep or breathing disorders. ResMed is focusing on converting more patients from diagnosis to long-term therapy, particularly as more patients enter the healthcare system through consumer technology and GLP-1-related care.

To support growth, ResMed has engaged in several acquisitions, including Ectosense, Somnoware, and VirtuOx, to enhance home sleep apnea testing and physician workflows. The company operates globally with a presence in over 140 countries, providing CPAP machines and Software as a Service (SaaS) solutions for respiratory care.